Explore jobs
Find specific jobs
Explore careers
Explore professions
Best companies
Explore companies
G1 Therapeutics revenue
G1 Therapeutics's revenue is $82.5 million.
What is G1 Therapeutics's revenue?
- G1 Therapeutics's revenue growth from 2020 to 2023 is 82.2%.
- G1 Therapeutics has 148 employees, and the revenue per employee ratio is $557,506.
- G1 Therapeutics's peak quarterly revenue was $42.4M in 2023(q2).
- G1 Therapeutics peak revenue was $82.5M in 2023.
- G1 Therapeutics annual revenue for 2022 was 51.3M, 62.98% growth from 2021.
- G1 Therapeutics annual revenue for 2023 was 82.5M, 60.84% growth from 2022.
On this page
Zippi applies for you, and finds you a job.
G1 Therapeutics historical revenue
G1 Therapeutics's peak revenue was $82.5M in 2023. The peak quarterly revenue was $42.4M in 2023(q2).
G1 Therapeutics's revenue increased from $45.3m in 2020 to $82.5M currently. That's a 82.2% change in annual revenue.
G1 Therapeutics annual revenue
G1 Therapeutics annual revenue over time
| Fiscal year / year | G1 Therapeutics revenue |
|---|---|
| 2020 | $45.3M |
| 2021 | $31.5M |
| 2022 | $51.3M |
| 2023 | $82.5M |
Rate G1 Therapeutics' financial transparency
G1 Therapeutics annual growth
G1 Therapeutics saw the greatest revenue growth in 2022, when revenue increased by 62.98%.
G1 Therapeutics had the lowest revenue growth in 2021, when revenue changed by -30.49%.
G1 Therapeutics annual growth rate over time
| Year | G1 Therapeutics growth |
|---|---|
| 2021 | -30%↓ |
| 2022 | 63%↑ |
| 2023 | 61%↑ |
G1 Therapeutics quarterly revenue over time
- Q1
- Q2
- Q3
- Q4
G1 Therapeutics quarterly growth rate over time
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2020 | - | $2.1M | $26.6M | $16.5M |
| 2021 | $14.2M | $6.6M | $4.9M | $5.8M |
| 2022 | $6.9M | $10.6M | $23.6M | $10.3M |
| 2023 | $12.9M | $42.4M | $12.3M | $14.9M |
| 2024 | $14.5M | $16.5M | - | - |
G1 Therapeutics jobs nearby
Do you work at G1 Therapeutics?
Did G1 Therapeutics meet its revenue projections?
G1 Therapeutics financial information
| CEO | Jack Bailey |
| Industry | Pharmaceuticals, Biotechnology & Life Sciences |
| Company Type | Public |
| Employees Number | 148 |
| Date Founded | 2008 |
| Headquarters | Parkton, North Carolina |
| Number of Locations | 2 |
| Revenue | $82.5M |
| Net Income | -$147,559,000 |
| Gross Proft | $75.3M (2023) |
| Tax Rate | -0.1% |
| Total Assets | $187,965,000 |
| Ticker | GTHX |
G1 Therapeutics jobs you might like
G1 Therapeutics financing
G1 Therapeutics received early financing of $762.9K on 2012-10-12.
| Series | Round size | Date |
|---|---|---|
| Series Unknown | $763K | 10/2012 |
| Debt Financing | $458K | 04/2013 |
| Series A | $12.6M | 10/2013 |
| Series B | $33M | 02/2015 |
| Series C | $47M | 05/2016 |
| Post Ipo Equity | $108.4M | 03/2018 |
| Post Ipo Equity | $195.1M | 09/2018 |
| Post Ipo Debt | $100M | 06/2020 |
G1 Therapeutics investors
| Investors | Security type |
|---|---|
| Hatteras Venture Partners | Series A |
| MedImmune Ventures Inc | Series A |
| Mountain Group Capital | Series A |
| Hatteras Venture Partners | Series B |
| Lumira Ventures | Series B |
| MedImmune Ventures Inc | Series B |
| Mountain Group Capital | Series B |
| RA Capital Management | Series B |
| ESHELMAN VENTURES LLC | Series B |
| Boxer Capital | Series B |
| Hatteras Venture Partners | Series C |
| Lumira Ventures | Series C |
| MedImmune Ventures Inc | Series C |
| Aju IB Investment | Series C |
| Franklin Resources, Inc. | Series C |
| Tavistock Group | Series C |
| Cormorant Asset Management | Series C |
| Mountain Group Capital | Series C |
| Cowen Inc. | Series C |
| Rock Springs Capital | Series C |
| RA Capital Management | Series C |
| ESHELMAN VENTURES LLC | Series C |
| HERCULES CAPITAL INC | Post Ipo Debt |
Search for jobs
Most in demand jobs
Zippia gives an in-depth look into the details of G1 Therapeutics, including salaries, political affiliations, employee data, and more, in order to inform job seekers about G1 Therapeutics. The employee data is based on information from people who have self-reported their past or current employments at G1 Therapeutics. The data on this page is also based on data sources collected from public and open data sources on the Internet and other locations, as well as proprietary data we licensed from other companies. Sources of data may include, but are not limited to, the BLS, company filings, estimates based on those filings, H1B filings, and other public and private datasets. While we have made attempts to ensure that the information displayed are correct, Zippia is not responsible for any errors or omissions or for the results obtained from the use of this information. None of the information on this page has been provided or approved by G1 Therapeutics. The data presented on this page does not represent the view of G1 Therapeutics and its employees or that of Zippia.
G1 Therapeutics may also be known as or be related to G1 THERAPEUTICS INC., G1 Therapeutics, G1 Therapeutics Inc, G1 Therapeutics, Inc. and G1Therapeutics, Inc.